Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTM1201AG
- Development stage
- Unknown
- Lead developer
- Brigham and Women's Hospital
- Administration
- Oral
01
Overview
LTM1201AG is an investigational drug being studied as part of a group of related compounds (including LTM1201AZ, LTM1201AT, and LTM1201AD) for the treatment of obstructive sleep apnea (OSA). The drug is administered before bedtime to evaluate its effects on the severity of OSA and upper airway muscle function during sleep. The precise mechanism of action, molecular target, and chemical class for LTM1201AG have not been disclosed in public sources. It is currently under clinical investigation in older adults with moderate to severe OSA. The study is sponsored by Brigham and Women's Hospital[4][2][1].
- Other names
- LTM1201AGLTM-1201AGLTM 1201AG
Beyond the preview
Go deeper on LTM1201AG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTM1201AG.